Serina Therapeutics (Serina Therapeutics) EPS (Basic) : $1.14 (TTM As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Serina Therapeutics EPS (Basic)?

Serina Therapeutics's basic earnings per share (Basic EPS) for the six months ended in Mar. 2024 was $0.00. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2024 was $1.14.

Serina Therapeutics's EPS (Diluted) for the six months ended in Mar. 2024 was $0.00. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $0.29.

Serina Therapeutics's EPS without NRI for the six months ended in Mar. 2024 was $0.00. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2024 was -0.25.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Serina Therapeutics EPS (Basic) Historical Data

The historical data trend for Serina Therapeutics's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Serina Therapeutics EPS (Basic) Chart

Serina Therapeutics Annual Data

Trend

Dec21

Dec22

EPS (Basic)

-0.58

-1.24

Serina Therapeutics Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Mar24
EPS (Basic)	-	-0.65	-0.59	1.14	-

Serina Therapeutics EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Serina Therapeutics's Basic EPS for the fiscal year that ended in Dec. 2022 is calculated as

Basic EPS (A: Dec. 2022 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-2.682	-	0)	/	2.167
	=	-1.24

Serina Therapeutics's Basic EPS for the quarter that ended in Mar. 2024 is calculated as

Basic EPS (Q: Mar. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-9.437	-	0)	/	8.569
	=	-1.10

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $1.14

Serina Therapeutics (AMEX:SER) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Serina Therapeutics EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Serina Therapeutics's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Serina Therapeutics (Serina Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Serina Therapeutics Inc (AMEX:SER) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

2BO:Germany

Address

601 Genome Way, Suite 2001, Huntsville, AL, USA, 35806

Website

https://www.serinatherapeutics.com

Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers.

Serina Therapeutics (Serina Therapeutics) Headlines

From GuruFocus

Enable Injections and Serina Therapeutics Announce Agreement to Develop SER-252 in Combination with enFuse� for Advanced Parkinson's Disease

By Marketwired • 05-15-2024